Eli Lilly and Company (LLY)
NYSE: LLY · IEX Real-Time Price · USD
849.99
+12.70 (1.52%)
At close: Jun 7, 2024, 4:00 PM
852.99
+3.00 (0.35%)
After-hours: Jun 7, 2024, 7:59 PM EDT
Eli Lilly Revenue
Eli Lilly had revenue of $35.93B in the twelve months ending March 31, 2024, with 29.76% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $8.77B with 25.98% year-over-year growth. In the year 2023, Eli Lilly had annual revenue of $34.12B with 19.56% growth.
Revenue (ttm)
$35.93B
Revenue Growth
+29.76%
P/S Ratio
22.48
Revenue / Employee
$835,630
Employees
43,000
Market Cap
807.83B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | 22.32B | 826.20M | 3.84% |
| Dec 31, 2018 | 21.49B | 1.52B | 7.61% |
| Dec 31, 2017 | 19.97B | -1.25B | -5.88% |
| Dec 31, 2016 | 21.22B | 1.26B | 6.33% |
| Dec 31, 2015 | 19.96B | 343.10M | 1.75% |
| Dec 31, 2014 | 19.62B | -3.50B | -15.13% |
| Dec 31, 2013 | 23.11B | 509.70M | 2.25% |
| Dec 31, 2012 | 22.60B | -1.68B | -6.93% |
| Dec 31, 2011 | 24.29B | 1.21B | 5.25% |
| Dec 31, 2010 | 23.08B | 1.24B | 5.68% |
| Dec 31, 2009 | 21.84B | 1.46B | 7.19% |
| Dec 31, 2008 | 20.37B | 1.74B | 9.33% |
| Dec 31, 2007 | 18.63B | 2.94B | 18.75% |
| Dec 31, 2006 | 15.69B | 1.05B | 7.14% |
| Dec 31, 2005 | 14.65B | 787.40M | 5.68% |
| Dec 31, 2004 | 13.86B | 1.28B | 10.14% |
| Dec 31, 2003 | 12.58B | 1.51B | 13.59% |
| Dec 31, 2002 | 11.08B | -465.00M | -4.03% |
| Dec 31, 2001 | 11.54B | 680.30M | 6.26% |
| Dec 31, 2000 | 10.86B | 859.30M | 8.59% |
| Dec 31, 1999 | 10.00B | 766.10M | 8.29% |
| Dec 31, 1998 | 9.24B | 1.25B | 15.64% |
| Dec 31, 1997 | 7.99B | 989.40M | 14.14% |
| Dec 31, 1996 | 7.00B | 234.50M | 3.47% |
| Dec 31, 1995 | 6.76B | 1.05B | 18.42% |
| Dec 31, 1994 | 5.71B | 513.10M | 9.87% |
| Dec 31, 1993 | 5.20B | 235.40M | 4.74% |
| Dec 31, 1992 | 4.96B | -762.60M | -13.32% |
| Dec 31, 1991 | 5.73B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 379.49B |
| Johnson & Johnson | 81.80B |
| Merck & Co. | 61.40B |
| AbbVie | 54.40B |
| Novartis AG | 49.92B |
| AstraZeneca | 47.61B |
| Thermo Fisher | 42.49B |
| Abbott Laboratories | 40.33B |
LLY News
- 19 hours ago - Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks - PRNewsWire
- 1 day ago - Up 400% In 3 Years, Eli Lilly Stock Just Keeps Giving - Forbes
- 2 days ago - US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug - Reuters
- 3 days ago - Lilly announces departure of Anat Ashkenazi, chief financial officer - PRNewsWire
- 3 days ago - S&P Stocks To Trade In June - Forbes
- 4 days ago - Britain considers offering Lilly weight-loss drug on better terms than Wegovy - Reuters
- 4 days ago - Melissa Seymour to join Lilly as executive vice president of Global Quality - PRNewsWire
- 7 days ago - Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030, Goldman Sachs says - Business Insider